| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0924-8579(15)30002-9 |
| P698 | PubMed publication ID | 25867210 |
| P50 | author | Matteo Bassetti | Q88607142 |
| Inge C Gyssens | Q100504905 | ||
| Dilip Nathwani | Q114531596 | ||
| Emilio Bouza | Q37376561 | ||
| Helen Giamarellou | Q37838077 | ||
| P2093 | author name string | Andreas Voss | |
| Mark Wilcox | |||
| Jean Chastre | |||
| Serhat Unal | |||
| Arjana Tambic Andrasevic | |||
| Matthew Dryden | |||
| Silvano Esposito | |||
| Mo Baguneid | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic | Q24614464 | ||
| European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid | Q26823518 | ||
| Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement | Q27687541 | ||
| A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic | Q30425667 | ||
| High genetic diversity among community-associated Staphylococcus aureus in Europe: results from a multicenter study | Q31060816 | ||
| Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections | Q31134197 | ||
| A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay | Q33246169 | ||
| Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting | Q33770721 | ||
| Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients | Q34052619 | ||
| The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid | Q34091462 | ||
| Intrapulmonary pharmacokinetics of linezolid | Q34106719 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary | Q34158152 | ||
| Origin and evolution of European community-acquired methicillin-resistant Staphylococcus aureus | Q34237782 | ||
| Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis | Q34264291 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Practice guidelines for the diagnosis and management of skin and soft-tissue infections | Q34460523 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Clinical experience with daptomycin in Europe: the first 2.5 years | Q34681219 | ||
| Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California | Q34719851 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals | Q34999500 | ||
| Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. | Q35123155 | ||
| A practical guide to the treatment of complicated skin and soft tissue infections | Q35166376 | ||
| A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections | Q35328383 | ||
| Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis | Q35340007 | ||
| Epidemiology of methicillin-resistant staphylococci in Europe. | Q35612051 | ||
| Staphylococcus aureus CC398: host adaptation and emergence of methicillin resistance in livestock | Q35759760 | ||
| Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone | Q36072632 | ||
| Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. | Q40345173 | ||
| Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. | Q40600332 | ||
| Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership | Q40971694 | ||
| Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains | Q42143331 | ||
| Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia | Q42233083 | ||
| Community acquired MRSA in Europe. | Q42713254 | ||
| Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres | Q43073221 | ||
| Community-associated methicillin-resistant Staphylococcus aureus is prevalent in wounds of community-based injection drug users | Q43142984 | ||
| Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007. | Q43207777 | ||
| Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia | Q43777092 | ||
| Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies | Q43902450 | ||
| Intrapulmonary penetration of linezolid | Q44440587 | ||
| Early Switch and Early Discharge Opportunities in Intravenous Vancomycin Treatment of Suspected Methicillin-Resistant Staphylococcal Species Infections | Q44652724 | ||
| The problem with glycopeptides | Q45169360 | ||
| Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia | Q45279504 | ||
| Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis | Q45579971 | ||
| Risk stratification and outcome of cellulitis admitted to hospital | Q46178540 | ||
| Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus | Q46183056 | ||
| Community-acquired methicillin-resistant Staphylococcus aureus | Q46188100 | ||
| Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies | Q46214968 | ||
| Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model | Q46460992 | ||
| Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia | Q46589068 | ||
| Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment | Q46688174 | ||
| Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). | Q46805282 | ||
| Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. | Q51195354 | ||
| Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. | Q51643088 | ||
| Diagnosis related groups in Europe: moving towards transparency, efficiency, and quality in hospitals? | Q52883690 | ||
| Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). | Q54453191 | ||
| Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia | Q55966607 | ||
| Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus | Q59374940 | ||
| Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns | Q63859713 | ||
| Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study | Q64128667 | ||
| Is the "low-hanging fruit" worth picking for antimicrobial stewardship programs? | Q84190866 | ||
| Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies | Q86959042 | ||
| Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients | Q93911272 | ||
| Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia | Q36276932 | ||
| Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. | Q36409465 | ||
| Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat | Q36584656 | ||
| Oral antibiotic therapy of serious systemic infections | Q36658447 | ||
| Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections | Q36718474 | ||
| Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators | Q36927312 | ||
| Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. | Q37150599 | ||
| Treatment options for uncomplicated community-acquired skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus: oral antimicrobial agents | Q37290039 | ||
| Treatment options for skin and soft tissue infections: 'oldies but goldies'. | Q37533552 | ||
| Health economic issues in the treatment of drug-resistant serious Gram-positive infections | Q37600395 | ||
| Estimating the cost of health care-associated infections: mind your p's and q's. | Q37697184 | ||
| A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice | Q37707478 | ||
| Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia | Q37800310 | ||
| Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates | Q37809666 | ||
| Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. | Q38012736 | ||
| Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression | Q38052237 | ||
| MRSA infection in the neonatal intensive care unit | Q38102780 | ||
| Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence? | Q38110140 | ||
| Novel antibiotic treatment for skin and soft tissue infection | Q38185912 | ||
| European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid | Q38192097 | ||
| Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. | Q38199805 | ||
| Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria | Q38220130 | ||
| Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial | Q38468980 | ||
| In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains | Q39537168 | ||
| Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis | Q39816110 | ||
| Development of a guideline for the management of ventilator-associated pneumonia based on local microbiologic findings and impact of the guideline on antimicrobial use practices | Q39847958 | ||
| Interaction Between Vancomycin and Rifampin Against Staphylococcus aureus | Q39855356 | ||
| P304 | page(s) | S1-14 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | International Journal of Antimicrobial Agents | Q15724616 |
| P1476 | title | Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey | |
| P478 | volume | 45 Suppl 1 |
| Q26749132 | Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections |
| Q26747252 | Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe |
| Q52579373 | Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin. |
| Q58607144 | Expression of the Biofilm-Associated Genes in Methicillin-Resistant in Biofilm and Planktonic Conditions |
| Q37168719 | Host Physiologic Changes Induced by Influenza A Virus Lead to Staphylococcus aureus Biofilm Dispersion and Transition from Asymptomatic Colonization to Invasive Disease |
| Q91831719 | Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant Staphylococcus |
| Q59135453 | Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics |
| Q93044221 | Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial |
Search more.